A t sites of vascular injury, the subendothelial extracellular matrix is exposed to the blood and triggers sudden platelet activation and the formation of a fibrin containing thrombus. This process is essential to prevent excessive posttraumatic blood loss, but if it occurs inappropriately, for example, at sites of atherosclerotic plaque rupture, it can lead to vessel occlusion and ischemic infarction. In the clinical context of myocardial infarction, timely reopening of an occluded coronary artery by pharmacological thrombolysis or coronary intervention constitutes an effective therapeutic mean to limit cardiac damage. However, restoration of blood flow causes further cardiac damage, the so-called reperfusion injury (RI). The mechanisms of myocardial RI are not fully understood; thus, it is possible that thrombus formation by platelets in reperfused microvessels could contribute to this process. Furthermore, thrombus fragmentation by thrombolysis or coronary balloon angioplasty might add to the occlusion of microvessels by distal embolization. Additionally, platelets release factors that potentially increase RI without mechanical obstruction of microvessels. Activated © 2016 American Heart Association, Inc. Objective-The objective of this study was to investigate the effects of platelet inhibition on myocardial ischemia-reperfusion (IR) injury. Approach and Results-Timely restoration of coronary blood flow after myocardial infarction is indispensable but leads to additional damage to the heart (myocardial IR injury). Microvascular dysfunction contributes to myocardial IR injury. We hypothesized that platelet activation during IR determines microvascular perfusion and thereby the infarct size in the reperfused myocardium. The 3 phases of thrombus formation were analyzed by targeting individual key platelet-surface molecules with monoclonal antibody derivatives: (1) adhesion (anti-glycoprotein [GP]-Ib), (2) activation (anti-GPVI), and (3) aggregation (anti-GPIIbIIIa) in a murine in vivo model of left coronary artery ligation (30 minutes of ischemia followed by 24 hours of reperfusion). Infarct sizes were determined by Evans Blue/2,3,5-triphenyltetrazolium chloride staining, infiltrating neutrophils by immunohistology. Anti-GPVI treatment significantly reduced infarct size versus control, whereas anti-GPIb or anti-GPIIbIIIa antibody fragments showed no significant differences. Mechanistically, anti-GPVI antibody-mediated reduction of infarct size was not because of impaired Ca 2+ signaling or platelet degranulation because mice deficient in store-operated calcium channels (stromal interaction molecule 1, ORAI1), α-granules (Nbeal2 
platelets secrete granule contents, including chemokines (eg, RANTES [regulated on activation, normal T cell expressed and secreted], platelet factor 4), cytokine-like factors (eg, interleukin-1β, CD40-ligand, β-thromboglobulin), and coagulation factors (eg, Factor V, Factor XI, PAI-1 [plasminogen activator inhibitor-1], plasminogen), which activate the endothelium and enhance leukocyte adhesion, extravasation, and the formation of interstitial edema. Activated platelets also bind to leukocytes in the blood and interact with endothelial cells by direct cell-cell contacts. 1, 2 Basically, thrombus formation can be divided into 3 distinct phases 3 : (1) adhesion, (2) activation, and (3) aggregation of platelets with the platelet membrane receptors glycoprotein (GP)Ib-V-IX, GPVI, and GPIIbIIIa being involved in all these steps: platelets can adhere to hypoxic endothelial cells by binding of their GPIb receptor to von Willebrand factor (vWF) on the endothelial surface. Locally exposed subendothelial matrix proteins, such as collagens, facilitate the attachment of platelets by the GPVI receptor. Subsequent platelet activation involves an increase in cytosolic Ca 2+ concentration, which is mediated by the stromal interaction molecule 1 (STIM1), a key regulatory protein of store-operated Ca 2+ entry (SOCE), and a calcium releaseactivated calcium channel protein 1 (Orai-1) as principal Ca 2+ entry channel. 4 These processes lead to the activation of platelet GPIIbIIIa, the release of granules, and finally platelet aggregation.
Therapeutics that interfere with platelet aggregation, like acetylsalicylic acid, ADP (adenosine-di-phosphate) receptor antagonists (clopidogrel), antagonists of the major platelet integrin αIIbβ3 (GPIIbIIIa), and phosphodiesterase inhibitors, 5 are well established in the clinical setting of acute coronary syndrome, limiting thrombus formation. Although being effective, they are all linked to an increased risk of life-threatening bleeding events. A better understanding of the mechanisms leading to platelet activation in the context of myocardial RI might help to identify new therapeutic targets to limit platelet-induced RI without further increasing the risk for clinically relevant bleeding. In the present study, we hypothesized that platelet activation contributes to RI, and we aimed to identify targets that reduce ischemia-reperfusion (IR) injury with minimal or comparable risk of bleeding to the current therapeutic standards.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Inhibition of GPVI Significantly Reduces Myocardial Reperfusion Injury
All 3 phases of platelet activation were experimentally addressed for their effect on IR injury, namely (1) initial adhesion, (2) activation, and (3) aggregation (Figure 1 ). The infarct size per area at risk (INF/AAR) was the primary end point studied because it reflects the most meaningful clinical parameter. In each experimental series, individual controls were used.
Platelet Adhesion
The initial capture of flowing platelets was blocked by inhibiting the binding of GPIb-V-IX to vWF ( Figure 1A) . In a first approach, anti-GPIb F(ab) fragments were given at reperfusion. As a second approach, anti-GPIb F(ab) fragments were injected 10 minutes after reperfusion to evaluate a possible relevance of timing. Figure 3A ).
Platelet Activation
GPVI can be irreversibly downregulated on circulating platelets by antibody-induced ectodomain shedding. 6 We administered the anti-GPVI antibody 6 days before the induction of myocardial IR to deplete GPVI from platelets. 7, 8 Loss of GPVI from the platelet surface was confirmed by flow cytometry at day 5 after injection of the anti-GPVI antibody ( Figure  IA 
Platelet Aggregation
Firm adhesion and thrombus growth ( Figure 1C ) were inhibited by anti-GPIIbIIIa (Fab) 2 fragments or the depletion of C-type lectin-like receptor 2 in circulating platelets by injection of an anti-C-type lectin-like receptor 2 antibody on day 6 before the experiment. 9 In Figure 2C ).
Taken together, only the inhibition of platelet activation by GPVI but not the inhibition of adhesion or aggregation by receptor blockade reduced infarct size after 30 minutes of ischemia and 24 hours of reperfusion. Figure 3C ). In conclusion, GPVI-dependent promotion of IR injury does not require SOCE or the release of α-and dense granule content.
Enhanced Microperfusion in Anti-GPVI-Treated Mice
Reduced microvascular obstruction might explain the protective effects of anti-GPVI treatment. To test for this, we measured microperfusion after 30 minutes of ischemia and 24 hours of reperfusion using a fluorescent microsphere protocol in mice treated with PBS (control), anti-GPVI antibody (platelet inhibition, reduced infarct size), and anti-GPIb F(ab) (platelet inhibition, no reduced infarct size; Figure III in the online-only Data Supplement). To measure the total perfusion, blue fluorescent microspheres were injected. To assess the area at risk, red fluorescent microspheres were injected after the reocclusion of the coronary artery. The area at risk (no red microspheres) was similar in all groups. However, perfusion of the reperfused ischemic area (blue microspheres) was significantly increased in animals treated with anti-GPVI (PBS versus anti-GPVI versus anti-GPIb: 0.74±0.10 versus 1.02±0.10 versus 0.90±0.08; [n=5]; Figure 4 ). Thus, despite similar platelet inhibiting capacity, only anti-GPVI, but not anti-GPIb, treatment increased the perfusion of the previously ischemic area after reperfusion.
Platelet Inhibition Induces Myocardial Hemorrhage
A severe side effect of platelet inhibition could be intramyocardial hemorrhage after myocardial infarction, which might potentially abolish protective antithrombotic effects. Because intramyocardial hemorrhage is difficult to quantify by immunohistology, we visualized hemorrhage by magnetic resonance imaging in a subset of mice ( Figure IV in the online-only Data 2+ entry was studied using chimeric mice that lack stromal interaction molecule 1 (STIM1) or Orai-1 in platelets. Binding of GPVI to collagen was inhibited by anti-GPVI antibody. Released adenosine-di-phosphate (ADP) and thromboxane A2 (TxA 2 ) amplify integrin activation on adherent platelets and mediate thrombus growth by activating additional platelets. C, Firm adhesion and thrombus growth was inhibited by anti-GPIIbIIIa F(ab) 2 , whereas stabilization of the growing thrombus through C-typelectin-like receptor 2 (CLEC-2) was blocked by anti-CLEC-2 antibody. Modified from Varga-Szabo et al. 3 GP indicates glycoprotein. Supplement) of the respective treatment groups and a pool of all sham-operated mice, assuming that the occurrence of hemorrhage is highly unlikely in the latter (Table I in the onlineonly Data Supplement). We found that in both groups, the anti-GPIb and the anti-GPVI treatment, hemorrhage occurred (anti-GPIb: 3 out of 9 mice analyzed developed a hemorrhage; anti-GPVI: 2 out of 9 mice analyzed developed a hemorrhage). In addition, ejection fraction was determined based on magnetic resonance imaging measurements. There was no statistical difference in the ejection fraction of anti-GPIb or anti-GPVI antibody treatment versus control ( Figure V in the online-only Data Supplement).
Anti-GPVI and Anti-GPIb AntibodyTreated Mice Show Decreased Numbers of Leukocytes in the Reperfused Myocardium
Multiple interaction mechanisms between platelets and leukocytes lead to recruitment and activation of inflammatory cells to sites of platelet activation. We analyzed leukocytes in reperfused myocardium by immunohistology and found the numbers of neutrophils in the myocardium to be reduced both in anti-GPVI-and anti-GPIb-treated mice ( Figure 5 ).
As an additional approach, we performed flow cytometric analysis of intramyocardial leukocytes. Accordingly, we found a reduced amount of CD45 + leukocytes infiltrating the ischemia-reperfused zone of anti-GPVI-and anti-GPIb-treated mice (PBS versus anti-GPVI versus anti-GPIb: 3.9±1.7% versus 1.3±0.6% versus 0.9±0.2%; [n≥6]; Figure 6A ), but no differences in the frequencies of infiltrating CD3 + T cells ( Figure 6B ) and their CD4 + ( Figure 6C ) and CD8 + subsets ( Figure 6D ). Taken together, anti-GPVI and anti-GPIb were both able to reduce neutrophil infiltration after IR.
Discussion
In the present study, we investigated the hypothesis that pathological platelet activation contributes to myocardial RI. To test this hypothesis, we studied the 3 main phases of plateletdependent thrombus formation individually 3 : (1) initial adhesion, (2) activation, and (3) firm adhesion/aggregation.
The initial capture of flowing platelets was inhibited with an anti-GPIb antibody that interrupted the interaction of GPIb-V-IX with vWF immobilized on exposed collagens. Neither infarct sizes nor microperfusion were affected by this approach. Platelet aggregation, spreading on the exposed extracellular matrix of the injured vessel wall, and thrombus formation are mediated by the binding of integrin αIIbβ3 (GPIIbIIIa) to its ligands fibrinogen, fibronectin, and vWF. This process was inhibited using an anti-GPIIbIIIa antibody. This approach did not significantly alter infarct size.
After the initial capturing of flowing platelets, the collagen receptor GPVI can bind to its ligand and initiate cellular activation. We studied the role of GPVI in myocardial RI by using an anti-GPVI antibody that induces irreversible downregulation of the GPVI receptor on the surface of circulating platelets. This is different from a previous approach targeting GPVI-mediated platelet activation in myocardial RI: Schönberger et al administered the dimeric soluble fusion protein GPVI-Fc Revacept, consisting of the extracellular part of the human platelet collagen receptor GPVI and the Fc domain of human IgG1. Mechanistically, this recombinant GPVI-Fc binds to activated endothelium mainly via vitronectin and inhibits platelet/endothelial interaction, 10 whereas the pretreatment with the anti-mouse GPVI antibody JAQ1 11 used in the present study leads to irreversible depletion of GPVI on circulating platelets, resulting in abolished responses of the cells to collagen. Administration of Revacept reduced infarct size, preserved cardiac function, and attenuated platelet-mediated inflammatory responses after transient myocardial ischemia. 10 Reduction of infarct size after the administration of GPVI-Fc was associated with reduced GPVI-induced platelet degranulation and release of proinflammatory cytokines. 10 Revacept has already been tested in a first-in-human study (phase I) and appeared to be safe and well-tolerated with a clear dosedependent pharmacokinetic profile. 12 In our present study, we studied a new approach to target GPVI in myocardial IR, using the anti-GPVI antibody JAQ1. 11 Here, GPVI is irreversibly downregulated on circulating platelets by antibody-induced ectodomain shedding. 6 Using this anti-GPVI antibody, we found significantly reduced INF/ AAR and improved myocardial microperfusion after RI, providing a promising alternative to Revacept. Both approaches a n t i -G P I b c o n t r o l a n t i -G P V I underline the therapeutic relevance of the GPVI pathway for myocardial IR injury.
How Does Anti-GPVI Treatment Confer Protection?
The immune system has long been recognized as an important mediator of cardiac RI. Neutrophils infiltrate the myocardium within minutes after ischemia, and they mediate ischemic inflammation and aggravate infarct size. 13 Siminiak et al described a cross talk between neutrophils and platelets 14 that can result in capillary plugging in the coronary microcirculation and thereby contribute to the no reflow phenomenon. 15 Further support for a link between platelets and neutrophils in cardioprotection comes from a study by Takaya et al, 16 examining Fc receptor-γ chain-deficient mice. The Fc receptor-γ chain is noncovalently associated with GPVI in the platelet membrane and is essential for the expression of and signal transduction by this receptor.
11, 16 Takaya et al showed that Fc receptor-γ chain-deficient mice were protected from myocardial IR injury. Myeloperoxidase activity, an indicator for neutrophil infiltration, and the adhesion of platelets with neutrophils were reduced in Fc receptor-γ chain-deficient mice, whereas CD11b expression on neutrophils was not altered. 16 After GPIb-and GPVI inhibition, we found reduced numbers of neutrophils in the infarct zone. Reduced neutrophil numbers correlated with smaller infarct sizes for the anti-GPVI-treated but not for anti-GPIb-treated mice. Therefore, the postulated cross talk between neutrophils and platelets does not fully explain the protective effect of anti-GPVI antibody treatment.
Importantly, we observed significantly improved microperfusion in mice treated with anti-GPVI-but not in mice treated with anti-GPIb antibody-in the ischemic area after reperfusion. An explanation of improved microperfusion after GPVI inhibition might be given by a recent publication of Mammadova-Bach et al. 17 Here, GPVI was identified as a platelet receptor for polymerized fibrin, which can amplify thrombin generation and recruit circulating platelets to clots. 17 This publication highlights the central function of GPVI not only in the phase of platelet activation, but also in the phase of thrombus growth and the stabilization of thrombi. 17 Therefore, the function of GPVI as a receptor for polymerized fibrin might explain the significantly improved microperfusion in anti-GPVI-treated mice in comparison to anti-GPIb treatment, which only affects the initial capture of flowing platelets. A significant limitation of the anti-GPVI treatment was an increased prevalence of myocardial hemorrhage, which might be responsible for the observation that the infarct sparing effect did not lead to an immediately improved ejection fraction compared with the control treatment group. Finally, the cross talk between blood platelets and immune cells can also be influenced by microparticles. These are membrane-coated vesicles, which can be released by many cell types during activation and apoptosis. Platelet-derived microparticles were identified as a contributing factor to rheumatoid arthritis, 18, 19 where their generation crucially depends on GPVI. This is in accordance with a previous study showing GPVI activation to increase the formation of platelet-derived microparticles in whole blood samples. 20 It seems plausible that the GPVI inhibition might affect platelet-derived microparticle formation in an IR setting, but this link was not assessed in our current study. 18 To further decipher the mechanism of GPVI-mediated reduction of infarct size, series of platelet-specific knockout mice (Stim1 ] i levels mediates shape change, integrin αIIbβ3 activation, thromboxane formation, and secretion of granule contents, whereas high and sustained intracellular calcium [Ca 2+ ] i rises are required for the procoagulant response. 21 Here we hypothesized that GPVI-dependent promotion of RI might be related to those components. However, our experiments clearly showed that STIM1/Orai1-dependent SOCE in platelets is not required for this pathological process.
The content of platelet-dense granules (δ-granules) and α-granules promote platelet aggregation, thrombus formation, and stability (by means of calcium, serotonin, ADP, and ATP release; δ-granules) or mediate adhesiveness and inflammation (by mediators, such as vWF, fibrinogen, P-selectin, interleukin-1β, interleukin-8, α-granules). 22 Activation of GPVI leads to the degranulation of platelet α-and dense granules. 23 Nbeal2 -/-mice lack α-granules in megakaryocytes and platelets. 22 Mice carrying an inactivating point mutation in the Unc13d gene (Unc13d −/− mice), leading to the absence of Munc13-4 in platelets, display abolished platelet-dense granule secretion and reduced α-granule release. 24 To date, little is known about the granules' contribution to thromboinflammatory processes like myocardial RI. Here we found no significant alterations in infarct sizes in either Nbeal2 −/− or Unc13d −/− mice, arguing against a significant role of degranulation in the pathophysiology of myocardial IR injury.
What Explains the Different Results of Myocardial Infarction and Stroke?
The role of platelets in ischemic stroke has been extensively studied. GPIb was identified as an attractive target for the clinical development of an anti-thromboinflammatory drug, significantly reducing cerebral infarcts. 25 Treating mice with anti-GPIbα Fab 1 hour before and 1 hour after middle cerebral artery occlusion clearly reduced ischemic lesions compared with controls. 26 Interaction of the GPIb-V-IX complex with vWF is transient and reduces the velocity of the cells, thereby enabling interactions between the lowaffinity platelet collagen receptor, GPVI, and collagen. 27 In acute experimental stroke, depletion of GPVI diminished the infarct volume significantly, but to a lesser extent than GPIb, 26 whereas in our model of the ischemic and reperfused heart, solely depletion of GPVI clearly reduced INF/AAR. Although in a small subset of IR mice, intramyocardial hemorrhage occurred in anti-GPVI-and anti-GPIb-treated mice, in a model of acute experimental stroke, mice receiving anti-GPIbα Fab or anti-GPVI mAbs did not show hemorrhagic transformation by serial magnetic resonance imaging studies. Blockade of the final common pathway of platelet aggregation with anti-GPIIbIIIa F(ab) 2 fragments dose-dependently increased the incidence of intracerebral hemorrhage after transient middle cerebral artery occlusion. 26 This led to an improved outcome after stroke in anti-GPVI-treated animals.
Our differing findings in the myocardium might also be explained by differences in intensity of shear stress. Under conditions of low shear, such as those found in larger arteries and veins, platelet adhesion to the vessel wall mainly involves binding to fibrillar collagens, fibronectin, and laminin. 28 Although the initial contact of the GPIb-V-IX complex with vWF is indispensable for platelet adhesion under conditions of high shear flow, 25 GPVI initiates platelet aggregation at both high and low shear stress. 29 Therefore, the assumed higher shear stress in the brain than in the heart 30 might be responsible for different ways of platelet activation.
Conclusions
IR injury can be reduced by inhibiting platelet activation via GPVI. This effect is not primarily because of an anti-thrombotic effect but rather indicates that platelets impair microvascular reperfusion. Still, more experiments on the preservation of cardiac function by the anti-GPVI antibody and hemorrhage are needed. Nevertheless, our data provide an indication that anti-GPVI treatment may be a valuable approach to reduce ischemic myocardial injury as an adjunct to standard antiplatelet therapy.
